There were more than 48,000 organ transplants in the United States last year. They’re commonplace now, but the practice was considered experimental only a half-century ago.

A very different kind of “hog farm” being built by United Therapeutics Corp. on the edge of Stewartville to raise gene-edited ...

According to United Therapeutics, the $110 million investment in Stewartville is expected to complete construction 2026 and be operational in 2027.

United Therapeutics Corporation ... which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable ...

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and manufactures organ replacements and treatments for organ disorders. The company’s three primary ...

That, along with 5 registration studies underway, several important data reads in the next 18 months and revolutionary progress on revolutionary organ programs makes United Therapeutics a truly ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers. Over the next ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results exceeding the market’s revenue ...

The animals producing United Therapeutics' three types of gene-edited organs will live their entire lives in the sterile environment. Dewey said the facility has the capacity to house up to 200 of ...